Saturna Capital Corp Makes New Investment in Dynavax Technologies Co. (NASDAQ:DVAX)

Saturna Capital Corp bought a new position in Dynavax Technologies Co. (NASDAQ:DVAX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,613 shares of the biopharmaceutical company’s stock, valued at approximately $174,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mizuho Markets Americas LLC boosted its position in Dynavax Technologies by 17.4% in the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Dynavax Technologies by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company’s stock worth $14,750,000 after purchasing an additional 32,347 shares during the last quarter. Bank of Montreal Can boosted its position in Dynavax Technologies by 8.3% in the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Dynavax Technologies by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company’s stock worth $11,893,000 after purchasing an additional 39,513 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in Dynavax Technologies by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Down 0.4 %

DVAX stock opened at $13.74 on Thursday. The business’s 50-day moving average price is $13.08 and its 200-day moving average price is $12.27. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The stock has a market cap of $1.70 billion, a P/E ratio of 76.33 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. On average, equities research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on DVAX shares. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.